- Company licensed to sell BioNTech’s mRNA vaccine in China reported its revenue rose 28.8% last year, with the Comirnaty vaccine bringing in over $157 million.
- Fosun Pharma’s revenue and profit both rose around 30% last year as Covid-19 vaccines and stake sales in its subsidiaries contributed to its top and bottom lines.
- The company’s gross margin fell sharply as some of its drugs were added to government procurement programs that promise higher sales but at heavy discounts.
For further details see:
Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins